ST易联众(300096) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥122,960,024.82, a decrease of 30.31% compared to the same period last year[4] - The net profit attributable to shareholders was -¥56,645,243.59, representing a decline of 112.64% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥60,445,238.84, down 87.14% from the previous year[4] - Total operating revenue for Q3 2022 was CNY 297.20 million, a decrease of 31.2% compared to CNY 432.41 million in the same period last year[25] - Net loss for Q3 2022 was CNY 232.90 million, compared to a net loss of CNY 136.01 million in Q3 2021, representing an increase in loss of 71.4%[26] - The total comprehensive income for Q3 2022 was -258,087,290.28 CNY, compared to -139,796,719.54 CNY in the same period last year, indicating a significant decline[27] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥1,516,217,717.91, a decrease of 9.21% from the end of the previous year[4] - Total assets decreased to CNY 1.52 billion, down 9.2% from CNY 1.67 billion at the end of the previous year[22] - Total liabilities increased to CNY 996.56 million, up 11.2% from CNY 896.42 million year-on-year[23] - The company's total current assets decreased from RMB 254,135,962.85 at the beginning of the year[20] Cash Flow - The operating cash flow net amount for the year-to-date was -¥209,052,441.01, an increase of 21.31% compared to the previous year[4] - The net cash flow from operating activities was -209,052,441.01 CNY, an improvement from -265,657,902.39 CNY year-over-year[30] - The net cash flow from investing activities was -16,038,659.97 CNY, a decline from a positive cash flow of 65,905,266.39 CNY in the previous year[30] - The net cash flow from financing activities was 30,287,324.41 CNY, compared to a negative cash flow of -76,414,084.14 CNY in the same period last year, showing a recovery[31] Shareholder Information - Total number of common shareholders at the end of the reporting period is 30,244[13] - Zhang Xi holds 16.21% of shares, totaling 69,681,649 shares, with 65,938,125 shares pledged[13] - WeDoctor Holdings Limited owns 9.58% of shares, amounting to 41,200,000 shares[14] - Tibet Wuwei Asset Management Co., Ltd. holds 5.00% of shares, totaling 21,499,900 shares[14] Operational Changes - The company has undergone changes in its supervisory board and securities affairs representative[18] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[26] - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the market[26] Inventory and Expenses - The company's inventory increased by 61.79% to ¥236,138,799.23 due to the rise in contract performance costs and goods dispatched[8] - Research and development expenses increased to CNY 154.64 million, up 10.9% from CNY 139.46 million in the previous year[26] Earnings Per Share - The company's basic and diluted earnings per share were both -¥0.1317, a decrease of 112.47% year-on-year[4] - Basic and diluted earnings per share were both -0.4213 CNY, worsening from -0.2442 CNY in the previous year[27]